Skip to main content

Table 2 Overview of dose constraints to the organs at risk per treatment arm

From: Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol

Organ

Constraints

Arm 1 (35x2Gy)

Arm 2 (20x3Gy)

Rectum

Va70

< 5%

 

V65

< 15%

 

V60

 

< 5%

V55

 

< 15%

Rectal wall

V25

 

< 80%

V30

< 80%

 

V35

 

< 50%

V41

< 50%

 

V50

 

< 25%

V60

< 25%

 

Mean Dose

< 30Gy

< 25Gy

Anus

Mean Dose

< 25Gy

<22Gy

Anal wall

V25

 

< 30%

V30

< 30%

 

Bladder

Dose0.1cc

< 105%

< 105%

V70

< 25%

 

V60

< 50%

< 25%

V50

 

< 50%

Femoral head

V45

 

< 10%

V55

< 10%

 

Penile bulb

 

ALARAb

ALARA

  1. aVolume; bAs low as reasonably achievable